We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • News
  • Blogs
  • Image IQ
  • Podcasts
  • Topics
  • Conferences
  • About

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • News
  • Blogs
  • Image IQ
  • Podcasts
  • Topics
  • Conferences
  • About

SUBSCRIBE: eNewsletter

John Schieszer

Mutations May Help Identify Laryngeal Tumors with Favorable Prognosis

  • John Schieszer
Dec 21, 2017

Researchers have identified mutations that may help distinguish which laryngeal cancer patients could benefit from therapy, since the disease is notoriously resistant to chemotherapeutic treatments.

Noncoding RNA Differences Found in African Americans with NSCLC

  • John Schieszer
Dec 19, 2017

Results from a recent study show that some differences exist in NSCLC gene expression from African Americans and European Americans, which could be leveraged to improve patient outcome in both populations.

Copanlisib May Benefit Patients with Relapsed or Refractory Indolent B-cell Lymphoma

  • John Schieszer
Dec 19, 2017

Data presented at the 2017 ASH meeting showed that copanlisib resulted in an improved response rate and low rate of severe toxicities in patients with relapsed/refractory B-cell lymphomas.

Combination Therapy Proposed for Multiple Myeloma and Mantle Cell Lymphoma

  • John Schieszer
Dec 12, 2017

A proof-of-concept study has demonstrated that resistance to treatment in multiple myeloma and mantle cell lymphoma could be linked to a protein called Nrf1, which appears to respond to proteasome insufficiency or pharmacological inhibition.

Predictive Genomic Markers of Response to VEGF-Targeted Therapy in RCC Patients

  • John Schieszer
Dec 12, 2017

Data presented at the 16th International Kidney Cancer Symposium showed that TP53 and VHL genes could act as predictive biomarkers for VEGF-targeted therapy for RCC.

Circulating Tumor DNA May Help Guide Therapy in Metastatic RCC Patients

  • John Schieszer
Dec 12, 2017

A new study demonstrates a relationship between radiographic tumor burden and the detection of circulating tumor DNA in patients with metastatic renal cell carcinoma.

Mogamulizumab May Benefit Patients with Cutaneous T-Cell Lymphoma

  • John Schieszer
Dec 12, 2017

A study presented at the 2017 ASH annual meeting showed that mogamulizumab resulted in significantly superior progression free survival and better outcomes compared with vorinostat in patients with previously treated CTCL.

Six-Month Analysis of CTL019 Demonstrates Sustained Responses in Refractory DLBCL Patients

  • John Schieszer
Dec 11, 2017

A potentially practice-changing study presented at 2017 ASH shows high rates of sustained complete response in patients with relapsed/refractory diffuse large B-cell lymphoma who were treated with CTL019 CAR T-cell therapy.

Selinexor Plus Sorafenib May Benefit Patients with Relapsed/Refractory FLT3-Mutated AML

  • John Schieszer
Dec 11, 2017

Data presented at the 2017 ASH annual meeting revealed that the combination of selinexor and sorafenib appears to be safe with clinical activity in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.

Mogamulizumab May Benefit Patients with Cutaneous T-Cell Lymphoma

  • John Schieszer
Dec 11, 2017

Data presented at 2017 ASH showed that mogamulizumab resulted in improved progression free survival (PFS), overall response rates (ORR), and better quality of life in patients with previously treated CTCL compared with vorinostat.

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
There are currently no available Sponsored Topics
There is currently no available content. Please check back soon.
Connect with Us
  • Twitter
  • Facebook
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.